Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Koichi Miyagawa, Josef Rosch, Frank Stanczyk, Kent Hermsmeyer

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

Original languageEnglish (US)
Pages (from-to)324-327
Number of pages4
JournalNature Medicine
Volume3
Issue number3
DOIs
StatePublished - 1997

Fingerprint

Medroxyprogesterone
Coronary Vasospasm
Progesterone
Steroids
Estradiol
Steroid hormones
Hormone Replacement Therapy
Progestins
Macaca mulatta
Cause of Death
Cardiovascular Diseases
Hormones
Wounds and Injuries

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. / Miyagawa, Koichi; Rosch, Josef; Stanczyk, Frank; Hermsmeyer, Kent.

In: Nature Medicine, Vol. 3, No. 3, 1997, p. 324-327.

Research output: Contribution to journalArticle

Miyagawa, Koichi ; Rosch, Josef ; Stanczyk, Frank ; Hermsmeyer, Kent. / Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. In: Nature Medicine. 1997 ; Vol. 3, No. 3. pp. 324-327.
@article{e39ed8f1ba234773ad1ff9bc75ff4f8e,
title = "Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm",
abstract = "Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.",
author = "Koichi Miyagawa and Josef Rosch and Frank Stanczyk and Kent Hermsmeyer",
year = "1997",
doi = "10.1038/nm0397-324",
language = "English (US)",
volume = "3",
pages = "324--327",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

AU - Miyagawa, Koichi

AU - Rosch, Josef

AU - Stanczyk, Frank

AU - Hermsmeyer, Kent

PY - 1997

Y1 - 1997

N2 - Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

AB - Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

UR - http://www.scopus.com/inward/record.url?scp=0031054234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031054234&partnerID=8YFLogxK

U2 - 10.1038/nm0397-324

DO - 10.1038/nm0397-324

M3 - Article

C2 - 9055861

AN - SCOPUS:0031054234

VL - 3

SP - 324

EP - 327

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -